Summary by Moomoo AI
BioVie reported Q2 fiscal 2025 net loss of $7.1 million, down from $8.4 million in Q2 2024, driven by lower research and development expenses. Revenue remained at zero while cash and equivalents stood at $24.4 million as of December 31, 2024. R&D expenses decreased to $4.7 million from $6.5 million year-over-year due to completion of prior clinical trials.The company made significant progress on its development programs, with plans to commence new Phase 2 trials for Parkinson's Disease and Long COVID in early 2025. BioVie received FDA clearance to proceed with the Parkinson's study and secured a $13.1 million Department of Defense grant for the Long COVID program. The company also continued development work on BIV201 for liver cirrhosis.During the quarter, BioVie strengthened its financial position through multiple equity offerings, raising gross proceeds of approximately $18.9 million. The company completed repayment of its outstanding notes payable in December 2024. Management noted that while substantial doubt exists about going concern, they continue to pursue strategic financing options to fund ongoing operations.
Comment(0)
Reason For Report